68Ga-PSMA-11 PET/CT评估前列腺癌的最佳时间点:无菌冷试剂盒示踪剂制备的可行性
这项前瞻性研究纳入50例前列腺癌患者(25例分期、25例生化复发),比较注射后20分钟早期半全身PET/CT与100分钟标准延迟腹盆腔PET/CT的检出率,并首次评估无菌冷试剂盒制备68Ga-PSMA-11的可行性。结果显示早期与延迟显像检出率相当,延迟显像SUVmax在可疑前列腺和淋巴结显著升高、骨病灶无显著升高;冷试剂盒将制备时间缩短至5分钟并提高约30%的放射性活度。
要点
- 无菌冷试剂盒制备68Ga-PSMA-11时间缩短至5分钟,每次68Ge/68Ga发生器洗脱的最终放射性活度提高约30%。
- 45例(90%)患者共分析158个病灶,早期与标准延迟68Ga-PSMA-11 PET/CT均提示恶性。
- 延迟显像SUVmax在可疑前列腺(11.6±8.2至14.8±1.0)和淋巴结(9.7±5.9至12.3±8.8)显著升高(p<0.001),骨病灶无显著升高(8.5±5.6至9.2±7.0,p=0.188)。
核心结论
- PSMA-11无菌冷试剂盒似乎可常规用于临床实践,其放射性核素制备时间较合成器法更短且更少依赖操作者。
- 早期68Ga-PSMA-11 PET/CT显像似乎可提供与标准延迟显像相当的检出率。
- 冷试剂盒缩短制备时间及早期PET/CT扫描的价值可能有助于定制显像方案,从而可能降低PET/CT中心成本并提高时间效率。
研究设计与样本
- 前瞻性研究,纳入50例前列腺癌患者(25例分期,25例生化复发)。
- 所有患者静脉注射2.0 MBq/kg体重的68Ga-PSMA-11(采用无菌冷试剂盒ANMI SA,Liege,Belgium制备),随后行注射后20分钟早期半全身PET/CT和注射后100分钟标准延迟腹盆腔PET/CT。
- 比较两次采集的68Ga-PSMA-11检出率,并分析生理性本底活性模式和肿瘤/本底比值。
主要发现
- 使用PSMA-11无菌冷试剂盒使总制备时间缩短至5分钟,每次68Ge/68Ga发生器洗脱的最终放射性活度提高约30%。
- 45例(90%)患者共分析158个病灶,早期和标准延迟68Ga-PSMA PET/CT图像均提示恶性。
- 延迟显像SUVmax在可疑前列腺显著升高(11.6±8.2至14.8±1.0,p<0.001),在淋巴结显著升高(9.7±5.9至12.3±8.8,p<0.001),在骨病灶无显著升高(8.5±5.6至9.2±7.0,p=0.188)。
- 早期图像可疑病灶的SUVmax足以支持正确判读标准(平均SUVmax 9.83±6.7)。
- 157个病灶中有26个SUV下降,多见于多发转移患者的亚厘米病灶,但未影响疾病分期或患者管理。
临床怎么用
- 作者认为PSMA-11无菌冷试剂盒似乎可常规用于临床实践,其制备时间更短且更少依赖操作者。
- 作者认为早期68Ga-PSMA-11 PET/CT显像似乎可提供与标准延迟显像相当的检出率。
- 作者认为冷试剂盒缩短制备时间和早期PET/CT扫描的价值可能有助于定制显像方案,可能降低PET/CT中心成本并提高时间效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this prospective study, we evaluated the optimal time-point for 68Ga-PSMA-11 PET/CT acquisition in the assessment of prostate cancer. We also examined, for the first time the feasibility of tracer production using a PSMA-11 sterile cold-kit in the clinical workflow of PET/CT centres. METHODS: Fifty prostate cancer patients (25 staging, 25 biochemical recurrence) were enrolled in this study. All patients received an intravenous dose of 2.0 MBq/kg body weight 68Ga-PSMA-11 prepared using a sterile cold kit (ANMI SA, Liege, Belgium), followed by an early (20 min after injection) semi-whole-body PET/CT scan and a standard-delay (100 min after injection) abdominopelvic PET/CT scan. The detection rates with 68Ga-PSMA-11 were compared between the two acquisitions. The pattern of physiological background activity and tumour to background ratio were also analysed. RESULTS: The total preparation time was reduced to 5 min using the PSMA-11 sterile cold kit, which improved the final radionuclide activity by about 30% per single 68Ge/68Ga generator elution. Overall, 158 pathological lesions were analysed in 45 patients (90%) suggestive of malignancy on both (early and standard-delay) 68Ga-PSMA PET/CT images. There was a significant (p < 0.001) increase in SUVmax on delayed images in suspicious prostates (11.6 ± 8.2 to 14.8 ± 1.0) and lymph nodes (LNs; 9.7 ± 5.9 to 12.3 ± 8.8), while bone lesions showed no significant increase (8.5 ± 5.6 to 9.2 ± 7.0, p = 0.188). However, the SUVmax of suspicious lesions on early images was adequate to support the criteria for correct interpretation (mean SUVmax 9.83 ± 6.7).In 26 of 157 lesions, but a decrease in SUV was seen, mostly in subcentimetre lesions in patients with multiple metastases. However, it did not affect the staging of the disease or patient management. The tumour to background ratio of primary prostate lesions and LNs showed a significant (p < 0.001) increase from the early to the standard-delay acquisition, but no significant increase was seen in bony lesions (p = 0.11). CONCLUSION: The PSMA-11 sterile cold kit seems to be feasible for use in routine clinical practice, and it has a shorter radionuclide preparation time and is less operator-dependent than the synthesizer-based production method. In addition, early 68Ga-PSMA-11 PET/CT imaging seems to provide a detection rate comparable with that of standard-delay imaging. Furthermore, the shorter preparation time using the 68Ga-PSMA-11 sterile cold kit and promising value of early PET/CT scanning could allow tailoring of imaging protocols which may reduce the costs and improve the time efficiency in PET/CT centres.
引用
- Beheshti M, Paymani Z, Brilhante J, et al. Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation? Eur J Nucl Med Mol Imaging. 2018. PMID: 29476228. doi:10.1007/s00259-018-3970-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。